Cordis Steeplechaser Third-Generation DES: Triple Crown Frontrunner?
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis plans to launch the third-generation Cypher Steeplechaser drug-eluting stent internationally in 2004, about 15 months after the global introduction of its second-generation Select model in the third quarter of 2003
You may also be interested in...
Conor Medsystems, Biotronik DES Would Compete With Established Players
Conor Medsystems expects technological characteristics - not price - will successfully position its CoStar drug-eluting stent against offerings from Johnson & Johnson and Boston Scientific
Conor Medsystems, Biotronik DES Would Compete With Established Players
Conor Medsystems expects technological characteristics - not price - will successfully position its CoStar drug-eluting stent against offerings from Johnson & Johnson and Boston Scientific
3.5 mm Cypher Availability To Reduce Problems With Over-Expansion – Cordis
Johnson & Johnson/Cordis says it will meet U.S. hospitals' orders for the Cypher drug-eluting stent by the end of the year, when Boston Scientific's Taxus drug-eluting stent is expected to reach the U.S. market